Key facts
- Famar’s last known valuation is $553.2M (Oct 2024).
- It has raised $5.2M; the latest was PE Growth/Expansion ($5.2M) in Sep 2025.
- Notable investors include European Bank for Reconstruction and Development, York Capital Management, ECM Partners (Slovenia), Metric Capital Partners, MidEuropa.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Famar
- ·The full record, as it builds
Funding rounds
No funding rounds for Famar are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Famar
Provider of contract manufacturing services intended for the pharmaceutical and healthcare industry. The company offers pharmaceutical manufacturing and development services starting from development to production and distribution of a broad range of pharmaceutical and consumer care products.
- Sector
- Business Products and Services (B2B)
- HQ
- Athens, Greece
- Founded
- 1949
- Employees
- 1,758
- Website
- famar-group.com/
- Ownership
- Privately Held (backing)
Famar doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Famar shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Famar in its N-PORT filings yet. We sweep new filings monthly.